Literature DB >> 18188674

Twenty-first Century ethics of medical research involving human subjects: achievements and challenges.

Antonios H Tzamaloukas1, Konstantin N Konstantinov, Emmanuel I Agaba, Dominic S C Raj, Glen H Murata, Robert H Glew.   

Abstract

The field of ethics in medical research has seen important developments in the last three decades, but it also faces great challenges in the new century. The purposes of this report are to examine the current status of ethics of medical research involving human subjects and the nature of the ethical challenges facing this research, to identify the weakness of the current system of safeguards for ethical research, and to stress the importance of the ethical character of the researcher, which is the safeguard that has the greatest potential for protecting the research subjects. Researchers appreciate the risks of human medical research that create ethical dilemmas and the need for an ethical compromise in order to proceed with the research. The main elements of the compromise, formulated primarily from experiences in the Second World War, include: (1) the dominant position of the ethical principle of autonomy; (2) the demand for a signed informed consent; (3) the likelihood of improving health with the research protocol, which must be approved by a duly appointed supervising committee; and (4) an acceptable risk/benefit ratio. The main weakness of this set of safeguards is the difficulty with obtaining a truly informed consent. The new challenges to ethical medical research stem from certain types of research, such as genetic and stem cell research, and from the increasing involvement of the industry in planning and funding the research studies. Developing medical researchers with an ethical character and knowledge about ethics in medicine may be the most effective safeguard in protecting participants of medical research experiments.

Entities:  

Mesh:

Year:  2008        PMID: 18188674     DOI: 10.1007/s11255-007-9319-2

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  26 in total

1.  How skeptical should we be about industry-sponsored studies?

Authors:  David Chadwick; Michael Privitera
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

2.  Trial blazers.

Authors:  Hannah Hoag
Journal:  Nature       Date:  2006-07-27       Impact factor: 49.962

3.  Investigator-initiated trials are more impartial.

Authors:  Bradley C Johnston; Sunita Vohra
Journal:  Nature       Date:  2006-09-14       Impact factor: 49.962

4.  Medicine. The future of personal genomics.

Authors:  Amy L McGuire; Mildred K Cho; Sean E McGuire; Timothy Caulfield
Journal:  Science       Date:  2007-09-21       Impact factor: 47.728

5.  Compact versus contract--industry sponsors' obligations to their research subjects.

Authors:  Michelle M Mello; Steven Joffe
Journal:  N Engl J Med       Date:  2007-06-28       Impact factor: 91.245

Review 6.  Ethical and legal aspects of cancer genetic testing.

Authors:  Kenneth Offit; Peter Thom
Journal:  Semin Oncol       Date:  2007-10       Impact factor: 4.929

7.  Nuremberg and the issue of wartime experiments on US prisoners. The Green Committee.

Authors:  J M Harkness
Journal:  JAMA       Date:  1996-11-27       Impact factor: 56.272

8.  The ethics of clinical research in the Third World.

Authors:  M Angell
Journal:  N Engl J Med       Date:  1997-09-18       Impact factor: 91.245

9.  The tuskegee syphilis study.

Authors:  W J Curran
Journal:  N Engl J Med       Date:  1973-10-04       Impact factor: 91.245

10.  Ethics and clinical research.

Authors:  H K Beecher
Journal:  N Engl J Med       Date:  1966-06-16       Impact factor: 91.245

View more
  2 in total

Review 1.  Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects.

Authors:  Kristina Hug; Göran Hermerén
Journal:  Stem Cell Rev Rep       Date:  2011-11       Impact factor: 5.739

Review 2.  Home dialysis as a first option: a new paradigm.

Authors:  Dimitrios G Oreopoulos; Elias Thodis; Ploumis Passadakis; Vassilis Vargemezis
Journal:  Int Urol Nephrol       Date:  2009-05-09       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.